LTR Pharma Limited
LTPLF
$0.27
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 297.80K | 151.00K | -- | -- | -- |
| Total Other Revenue | 32.20K | 32.20K | 32.20K | 16.10K | -- |
| Total Revenue | 330.00K | 183.20K | 32.20K | 16.10K | -- |
| Cost of Revenue | 548.60K | 689.20K | 824.10K | 824.10K | 824.10K |
| Gross Profit | -218.50K | -506.00K | -791.90K | -808.00K | -824.10K |
| SG&A Expenses | 2.40M | 2.21M | 2.01M | 1.51M | 1.00M |
| Depreciation & Amortization | 600.00 | 300.00 | -- | -- | -- |
| Other Operating Expenses | 389.40K | 333.00K | 274.80K | 153.70K | 33.00K |
| Total Operating Expenses | 4.81M | 4.71M | 4.59M | 3.41M | 2.24M |
| Operating Income | -4.48M | -4.53M | -4.56M | -3.39M | -2.24M |
| Income Before Tax | -4.50M | -4.54M | -4.57M | -3.40M | -2.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.50 | -4.54 | -4.57 | -3.40 | -2.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.50M | -4.54M | -4.57M | -3.40M | -2.24M |
| EBIT | -4.48M | -4.53M | -4.56M | -3.39M | -2.24M |
| EBITDA | -1.58M | -801.10K | -- | -- | -- |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.02 | -0.01 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| EPS Diluted | -0.03 | -0.03 | -0.03 | -0.02 | -0.01 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 584.98M | 571.23M | 557.47M | 833.07M | 1.11B |
| Average Diluted Shares Outstanding | 584.98M | 571.23M | 557.47M | 833.07M | 1.11B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |